Research Institute: Centenary Institute
Amount granted: $2.5 million
Year granted: 2016
The ACRF grant awarded in 2016, continues to support researchers to better understand the way cancer cells metabolise dietary nutrients. The state-of-the-art equipment funded by ACRF will provide critical information to the development of new cancer diagnostics and therapies.
Research at the ACRF Tumour Metabolism Laboratory focuses on the role of nutrient metabolism particularly in endometrial, brain and triple-negative breast tumours. These cancers are among the most difficult to treat of all cancers.
Endometrial cancer is diagnosed in more than 2,200 Australian women each year, accounts for 9.4% of all new cancer cases in women and has a 5-year survival rate of only 26%. Glioblastoma is the most common and most malignant brain tumour and in terms of years of life lost is the highest of all the malignant cancers. It is associated with a 5-year survival rate of less than 5% and a median survival rate of less than 15 months.
Triple-negative breast cancer (TNBC) is an aggressive form of cancer that accounts for 10-15% of all breast cancer cases. TNBC lacks a targeted therapy, has an increased rate of recurrence, and a lower 5-year survival rate compared to other breast cancer subtypes.
In addition to funding from ACRF, Cancer Institute NSW has committed to supporting the Laboratory by providing funding for scientists that will carry out the research.
The Laboratory is located at the ACRF Centenary Cancer Research Centre to which ACRF contributed $5 million in 2007.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.